Mountain Valley MD

We provide our global nutraceutical, vaccine and pharmaceutical partners with unprecedented product and market advantages.

MOUNTAIN VALLEY MD FILES PATENT TO PROTECT SCIENCE ACHIEVEMENT IN SOLUBILIZATION OF IVERMECTIN WITHOUT ORGANIC SOLVENTS AND ITS APPLICATION TO COVID-19 AND OTHER THERAPIES

November 11, 2020

Mountain Valley md's MIssion

Our mission is to help people live their best life by redefining how they consume and experience nutraceuticals, vaccines and pharmaceuticals.

Company Mission.

THe Quicksome™ advantage

Formulation Effectiveness

We take existing approved vaccines, drugs and nutraceuticals and increase delivery effectiveness into the body.

Quicksome™ integration

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective oral product formats.

Unprecedented Impact

  • Easy oral dissolve formats

  • Increased bioavailability

  • Minimizes variability

  • Precise dosing

  • Needleless format

  • Eliminates Cold Chain

  • Simplifies administration

IMPROVEd
molecule DELIVERY

Quicksome™ enables unprecedented delivery impact through sublingual and buccal formats that provide direct absorption into the bloodstream, dramatically improving drug efficacy, dosing and end-user experience.

Quicksome™ Eliminates:

The need to swallow a Pill or use a needle

Drug exposure to stomach acids

Drug absorption through the intestines

Liver metabolism and potential damage

Quicksome™

Quicksome™ End-user Benefits

Fast Acting

Delivers active ingredients into the body faster

Minimizes Side Effects

Reduces dosing and bypasses gastrointestinal tract

Rapid Dissolve

Quick water-free oral dissolution

Needleless

Painless, needle-free administration

No Pills

Eliminates swallowing and related digestion issues

Convenient

Easy to store, carry and consume

Our Value Proposition

We provide our partners with unprecedented market advantages while dealing with some of the most significant challenges facing their companies.

Loss of Patent Exclusivity

Extending Profitability Against Generic Drug Competitors

Driving Down Drug and Vaccine Costs While Increasing Profitability

Enabling Broader Distribution of Drugs and Vaccines

Expanding Production Capacity for Global Blockbuster Drugs

Eliminating Significant Costs and Wastage Associated with Cold Chain Storage Requirements

Our Value.

Our Progress

July 28, 2020

MOUNTAIN VALLEY MD HOLDINGS’ SUBSIDIARY COMPLETES ACQUISITION OF COLOMBIAN CANNABIS LICENCE SUITE

Read Press Release
July 31, 2020

U.S. FOOD AND DRUG ADMINISTRATION (FDA) POLIO LAB CONFIRMS MOUNTAIN VALLEY MD’S QUICKSOME™ TECHNOLOGY SUCCESSFULLY PRESERVES POLIO D ANTIGEN FOR VACCINES

Read Press Release
August 6, 2020

MOUNTAIN VALLEY MD ANNOUNCES SUCCESSFUL COMPLEXATION OF IVERMECTIN DRUG IN QUICKSOME™ ORAL STRIP AND COMMENCEMENT OF PRE-CLINICAL TRIALS

Read Press Release
August 7, 2020

MOUNTAIN VALLEY MD SECURES DISTRIBUTION RIGHTS FOR NEW AGRICULTURAL PLANT STIMULANT

Read Press Release
August 25, 2020

LEADING VACCINE EXPERT JOINS MOUNTAIN VALLEY MD ADVISORY BOARD TO ADVANCE QUICKSOME™ COMMERCIALIZATION

Read Press Release
October 2, 2020

MOUNTAIN VALLEY MD PROVIDES SUCCESSFUL QUICKSOME™ SUBLINGUAL PRE-CLINICAL TRIAL DOSING UPDATE

Read Press Release
November 11, 2020

MOUNTAIN VALLEY MD FILES PATENT TO PROTECT SCIENCE ACHIEVEMENT IN SOLUBILIZATION OF IVERMECTIN WITHOUT ORGANIC SOLVENTS AND ITS APPLICATION TO COVID-19 AND OTHER THERAPIES

Read Press Release
Read All News

Current News

“We believe this discovery to be a breakthrough that will enable the efficacy needed to treat respiratory infections such as COVID-19, influenza and tuberculosis by enabling the drug deposition into the airways and lungs through aerosol formulations and pulmonary delivery.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“The extrapolation of this technology achievement across multiple viral applications could be very significant and has the potential to positively impact human and animal health globally.”

- Dennis Hancock,
  President & CEO of Mountain Valley MD
  

“A needle-free, cost-effective, polio vaccine could be a major step towards global polio eradication. Mountain Valley MD’s Quicksome™ technology has already proven its ability to stabilize and preserve the Inactivated Poliovirus Vaccine (IPV) and I believe that this technology holds great promise in finally delivering a needle-free effective sublingual polio vaccine and probably many other globally needed vaccines as well.”

- Dr. John Clements,
  Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

“The FDA’s Polio D Antigen preservation results demonstrate that Mountain Valley MD’s proprietary and patented Quicksome™ low temperature strip manufacturing technology can be successfully applied to heat labile vaccines, complex proteins such as insulin or glucagon, peptides and other molecules and constructs that are sensitive to heat and oxidation.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“With encouraging FDA Polio Lab validation, Mountain Valley MD is continuing work on development of our proprietary vaccine adjuvants for Polio and the necessary pre-clinical trials to demonstrate the unprecedented impact of our Quicksome™ technology.”

- Dennis Hancock, President and CEO of Mountain Valley MD

“For decades scientists have been working to solve the problem of vaccine instability and cold chain distribution with little progress. Approaches such as micro-needle applications, lyophilization, spray drying, and others have not reached commercialization due to problems of complexity, cost, and long-term stability challenges.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“We believe Mountain Valley MD’s patented Quicksome™ technology revolutionizes drug and nutraceutical ingredient delivery for superior health outcomes by simultaneously addressing a multitude of key drug and nutraceutical product efficacy challenges, such as low bioavailability, high absorption variability and poor dosage control.”

- Dennis Hancock, President and CEO of Mountain Valley MD

“Many of the active ingredients contained in traditional pharmaceutical drugs and nutraceutical supplements are not well absorbed and suffer extensive degradation during first pass metabolism.  We feel this is exactly the problem that Mountain Valley MD’s direct-to-mouth Quicksome™ technology solves, dramatically improving bioavailability of compounds that are traditionally heavily metabolized by MAO enzymes, glucuronidation and other conjugation processes”.

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“We have an amazingly talented team that is working on solving some very advanced challenges in the health and wellness space.  To date we have done research and development work with more than 60 molecules for a variety of nutraceutical and pharmaceutical applications, including drugs, vaccines, the emerging mushroom space and cannabinoids.”

- Dennis Hancock, President and CEO of Mountain Valley MD

“For me personally, the idea that our delivery technology could help dispense drugs such as insulin or deliver vaccines into the body through a rapid dissolve sublingual strip and eliminate the need for painful needle injections is truly game changing.”

- Dennis Hancock, President and CEO of Mountain Valley MD
Our Progress.
Our Progress.

Subscribe for Updates

Stay plugged in on everything Mountain Valley MD.

THANK YOU FOR YOUR INTEREST IN OUR STORY.
Please check your inbox to confirm your subscription.
Oops! Something went wrong while submitting the form.
*By Clicking "Sign Up" You agree to Mountain Valley MD's Privacy Policy
Subscribe